Company Overview - Zeling Bio is a late-stage clinical biotechnology company focused on integrating structural biology, artificial intelligence, and clinically relevant disease models to develop highly differentiated small molecule therapies with first-in-class or best-in-class potential [2] - The company aims to address significant unmet medical needs in the fields of hematologic diseases, oncology, central nervous system, and immune/inflammatory diseases [2] - As of January 5, 2026, Zeling Bio's pipeline includes two core products (Fluorotidine Maleate and Puyisitan Injection), two clinical-stage candidates (ZL-82 and ZL-85), and four preclinical candidates (ZL-65, ZL-69, ZL-59, and ZL-89) [2] Product Pipeline - Fluorotidine Maleate (FM) is a novel triple-target inhibitor for treating myeloproliferative neoplasms, including myelofibrosis and polycythemia vera, with a focus on JAK2V617F mutations [3] - Puyisitan Maleate (PM) is a next-generation selective HDAC I/IIb inhibitor designed to meet unmet medical needs, featuring a unique non-linear triangular cap structure that enhances binding affinity and exhibits superior inhibitory activity compared to approved HDAC inhibitors [3] Financial Information - Zeling Bio currently has no products approved for commercial sale and has not generated any revenue from product sales [4] - For the fiscal year ending December 31, 2024, and the nine months ending September 30, 2025, the company reported other income and gains of RMB 19.661 million and RMB 7.126 million, respectively [4] - The company incurred operating losses of RMB 91.656 million for the fiscal year ending December 31, 2024, and RMB 119.043 million for the nine months ending September 30, 2025, primarily due to research and development expenses and changes in the carrying amount of redeemable debt [5][7] Industry Overview - Globally, cancer remains a leading cause of morbidity and mortality, with the oncology therapeutics market projected to grow from USD 167 billion in 2020 to USD 262.1 billion by 2024, at a compound annual growth rate (CAGR) of 11.9%, and expected to reach USD 724.9 billion by 2035 [8] - In China, the oncology therapeutics market is expected to grow from USD 25.8 billion in 2020 to USD 37.2 billion by 2024, with a CAGR of 13.1%, reaching USD 143.7 billion by 2035 [8] - The global myelofibrosis drug market is projected to grow from USD 1.6 billion in 2020 to USD 3 billion by 2024, with a CAGR of 15.9%, and expected to reach USD 6.4 billion by 2030 and USD 11.1 billion by 2035 [14][15]
赜灵生物递表港交所 两种候选药物已进入3期注册性临床试验阶段
Zhi Tong Cai Jing·2026-01-14 03:10